The evolution of functional assessments for spinal muscular atrophy (SMA) highlights the challenges of adapting pediatric ...
The US Food and Drug Administration has approved a new drug application for a tablet version of Evrysdi (risdiplam) for people living with spinal muscular atrophy (SMA).
Spinal muscular atrophy (SMA) is a debilitating genetic condition that’s usually fatal by a few years of age. But an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback